pffoundation
Plenary Session and Panel Discussion: Leveraging the PFF Care Center Network | Leaders: Vincent Cottin, MD, PhD; Kevin R. Flaherty, MD, MS; Jesse Roman, MD
Plenary Session and Panel Discussion - The Future of Clinical Trials in Pulmonary Fibrosis | Leaders: David J. Lederer, MD, MS; Kevin K. Brown, MD
Towards an Improved Quality of Life: Starring Oxygen Therapy and Pulmonary Rehab | Anne E. Holland, PhD
5th Place: Renea Jablonski, SIRT3, the anti-aging major mitochondrial deacetylase, is important for preventing pulmonary fibrosis
4th Place: Louise Hecker, Impaired Myofibroblast Dedifferentiation Contributes to Non-Resolving Fibrosis in Aging
3rd Place: Rachel Scheraga, The mechanosensitive transient receptor potential vanilloid 4 (TRPV4) ion channel mediates the pro-resolution/anti-fibrotic macrophage response to endotoxin (LPS)
2nd Place: Justin Oldham, TOLLIP, MUC5B and the Response to N-acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis
Question-and-Answer Period and Panel Discussion | Leaders: Ivan O. Rosas, MD; Christine Kim Garcia, MD, PhD
The Future of Drug Development in Pulmonary Fibrosis — A Regulatory Perspective | Janet Woodcock, MD